Effect of conjugated estrogens with and without medrogestone: A prospective study
article
Objective: To study the possible changes in serum lipids and lipoproteins during hormone replacement therapy with special emphasis on the possible effects brought about by the progestogen. Design: Open-label randomized prospective comparative study. Setting: Gynecological outpatient department of a university hospital. Patients: Thirty-three healthy hysterectomized postmenopausal women. Interventions: Continuous oral supplementation with conjugated estrogens, 0.625 mg daily, was administered either alone (group I; N = 18) or in combination with cyclic medrogestone, 5 mg daily during the last 12 days of each 28 days treatment cycle (group II; N = 15). Main outcome measure: Changes in serum lipids, lipoproteins and apolipoproteins after three, six and 13 treatment cycles. Results: After 1 year of treatment significant increases were observed in mean high-density lipoprotein (HDL) cholesterol, its subfractions, and apolipoprotein A-I in group I and II: HDL cholesterol: +25.2% and +12.1%, respectively; HDL<sub>2</sub> cholesterol: +47.4% and +23.5%, respectively; HDL<sub>3</sub> cholesterol: +18.1% and +11.2%, respectively; apolipoprotein A-I: +23.0 and +14.8%, respectively. Comparing the two study groups no significant differences were found in lipid changes during the study period, except for HDL<sub>2</sub> cholesterol. Conclusion: Supplementation with conjugated estrogens, with and without medrogestone, and given for a longer period, demonstrated a beneficial influence on serum lipoproteins with almost no differences between the two treatment regimens.
Chemicals/CAS: Apolipoproteins; Cholesterol, 57-88-5; Cholesterol, HDL; Cholesterol, LDL; Estrogens, Conjugated (USP); Lipids; Lipoproteins; Medrogestone, 977-79-7; Triglycerides
Chemicals/CAS: Apolipoproteins; Cholesterol, 57-88-5; Cholesterol, HDL; Cholesterol, LDL; Estrogens, Conjugated (USP); Lipids; Lipoproteins; Medrogestone, 977-79-7; Triglycerides
Topics
Administration, OralApolipoproteinsCholesterolCholesterol, HDLCholesterol, LDLClimactericDose-Response Relationship, DrugDrug Administration ScheduleEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansHysterectomyLipidsLipoproteinsMedrogestoneMiddle AgedProspective StudiesTriglycerides
TNO Identifier
280585
ISSN
03785122
Source
Maturitas, 19(1), pp. 33-42.
Pages
33-42
Files
To receive the publication files, please send an e-mail request to TNO Repository.